MINNEAPOLIS, USA, and TEL AVIV, Israel, November 4, 2025 — Bio-Techne Corporation (NASDAQ: TECH) and Nucleai, an AI-driven precision-medicine company, have unveiled compelling clinical data showing that an AI-powered spatial-biology workflow can uncover predictive biomarkers in melanoma patients receiving immunotherapy. The collaborative results, presented at the 2025 Society for Immunotherapy of Cancer (SITC) Annual Meeting, demonstrate the transformative potential of combining Bio-Techne’s COMET™ spatial-proteomics platform with Nucleai’s AI-based tissue analytics. Together, the companies profiled tumor biopsies from patients with advanced melanoma, identifying tumor–immune interactions that correlate with survival outcomes and therapy response, marking a new frontier in the evolution of precision immuno-oncology.
Science Significance
At the heart of this breakthrough lies the fusion of spatial-biology technology and machine learning analytics. Bio-Techne’s COMET™ system enabled high-plex multiplex immunofluorescence imaging across 28 protein biomarkers, generating rich spatial maps of the tumor microenvironment. Nucleai’s AI operating system then integrated spatial, molecular, and histological data to detect patterns of immune-cell positioning, clustering, and signaling that traditional analyses often miss. Notably, researchers discovered that proximity between PD-L1-positive tumor cells and CD8-positive T-cells—as well as co-localization of ICOS-positive helper T-cells—strongly predicted positive immunotherapy responses and longer progression-free survival. The findings illustrate how spatial context, not just molecular abundance, drives immune engagement and therapeutic effectiveness. This convergence of AI pattern recognition and spatial proteomics represents a paradigm shift for biomarker discovery, enabling faster, data-rich insights that can guide personalized cancer therapy selection.
Regulatory Significance
The collaboration has far-reaching implications for the regulatory validation of digital biomarkers. Both Bio-Techne and Nucleai operate within frameworks compliant with Good Clinical Practice (GCP) and Good Laboratory Practice (GLP) standards, ensuring analytical reproducibility and data integrity. The AI-driven biomarker workflow aligns with regulatory initiatives under the FDA’s 21st Century Cures Act and Biomarker Qualification Program, which emphasize cross-disciplinary data integration and clinical applicability. As spatial-biology and digital pathology mature, this partnership sets a precedent for regulatory-ready digital biomarkers capable of supporting companion diagnostics and clinical-trial enrichment strategies. By establishing traceable, validated analytical pipelines, the companies demonstrate that AI and multiplex imaging can meet the stringent requirements of regulatory science and accelerate the adoption of precision-immunotherapy guidance tools in clinical practice.
Business Significance
Advertisement
For Bio-Techne, this milestone cements its position as a global leader in spatial proteomics and translational research tools. The success of the COMET™ system underscores the company’s commitment to bridging basic research and clinical application through scalable, high-content technologies. Partnering with Nucleai expands its commercial footprint into the rapidly growing AI-powered pathology market, projected to surpass $15 billion by 2030. Nucleai, meanwhile, gains access to Bio-Techne’s robust oncology network, enhancing its role as a preferred AI analytics partner for pharmaceutical R&D and diagnostics. Beyond immediate scientific validation, this collaboration also signals a strategic alignment toward joint commercialization of AI-enabled clinical-decision platforms, enabling hospitals, CROs, and pharmaceutical sponsors to interpret spatial data at scale. The companies’ synergy exemplifies how integrated digital-biotech models can create sustained business value by turning scientific data into actionable, monetizable insights.
Patients’ Significance
For patients with advanced melanoma, the stakes are personal and profound. Although immunotherapies like checkpoint inhibitors have transformed outcomes, response rates remain inconsistent—only a fraction of patients achieve durable remission. By identifying spatial biomarkers predictive of treatment success, the Bio-Techne–Nucleai workflow could help clinicians select the right therapy for the right patient before treatment begins, sparing non-responders from ineffective or toxic regimens. Moreover, this technology may accelerate discovery of new biomarker-guided combinations, improving efficacy while reducing cost and treatment burden. In the long run, these insights promise to bring data-driven precision medicine from research laboratories directly into oncology clinics, enhancing both survival and quality of life for patients worldwide.
Policy Significance
This initiative supports a broader global policy agenda that prioritizes AI, digital-health integration, and ethical data governance in clinical research. Governments and health agencies across the U.S. and EU are investing heavily in frameworks that promote interoperability of clinical-research data while ensuring patient privacy and algorithmic transparency. The Bio-Techne–Nucleai collaboration exemplifies how such policies can be operationalized, offering a scalable, compliant model for AI adoption in regulated healthcare environments. It also reinforces international calls for standardized data exchange and open-science collaborations in oncology, aligning with the next phase of digital transformation under the Horizon Europe and U.S. National Cancer Plan initiatives.
The unveiling of the AI-powered spatial-biology workflow by Bio-Techne and Nucleai marks a defining moment in the evolution of precision immunotherapy. By merging high-resolution spatial mapping with advanced AI analytics, the companies have demonstrated how scientific ingenuity and digital innovation can converge to unlock hidden biological patterns within tumors. The resulting ability to predict response to immunotherapy offers a profound leap forward in patient stratification, trial design, and biomarker-based clinical practice. As regulatory and policy frameworks evolve to accommodate AI-enabled diagnostics, Bio-Techne and Nucleai stand at the forefront of a new era in predictive oncology, one where data becomes the most powerful medicine.
Source: Bio-Techne Corporation press release
